# 10x Genomics, Inc.

Summary updated: 2026-10-02T12:57:53.272465Z
Canonical: https://finbar.com/research/companies/10x-genomics-inc

## Overview

10x Genomics, Inc. is a life sciences technology company that develops integrated instruments, consumables and software for biological research. Its platforms support single-cell analysis (Chromium), spatial analysis of tissue (Visium) and in-situ analysis of gene expression and cellular location (Xenium). The company’s stated mission is to “accelerate the mastery of biology to advance human health.” [1](https://app.finbar.com/go?id=P88187382)[2](https://app.finbar.com/go?id=P26214981)[3](https://app.finbar.com/go?id=P90807722)[4](https://app.finbar.com/go?id=P23646988)

The company sells its products in more than 50 countries, with about 44% of FY2025 revenue coming from customers outside North America. It reported revenue of $642.8 million for FY2025 and had 1,178 employees as of December 31, 2025. [5](https://app.finbar.com/go?id=P4179124)[6](https://app.finbar.com/go?id=P51893903)[7](https://app.finbar.com/go?id=P23115492)[8](https://app.finbar.com/go?id=P26043104)
[1](https://app.finbar.com/go?id=P88187382)[2](https://app.finbar.com/go?id=P26214981)[3](https://app.finbar.com/go?id=P90807722)[4](https://app.finbar.com/go?id=P23646988)[5](https://app.finbar.com/go?id=P4179124)[6](https://app.finbar.com/go?id=P51893903)[7](https://app.finbar.com/go?id=P23115492)[8](https://app.finbar.com/go?id=P26043104)

## Products & services

10x Genomics’ Chromium platform comprises instruments, microfluidic chips, gel beads and reagents for single-cell analysis. The system partitions and barcodes cells or nuclei for pooled sequencing, supporting measurements including gene expression, cell-surface and intracellular proteins, chromatin accessibility, immune-receptor sequences (V(D)J), CRISPR perturbations and antigen binding. The company also lists QuantumScale Single Cell RNA and Single Cell Methylation kits among its offerings. [3](https://app.finbar.com/go?id=P90807722)[9](https://app.finbar.com/go?id=P59641181)

Its spatial biology products include Visium, which uses spatially barcoded tissue arrays to map molecular information in its tissue context, and Xenium, an in situ platform that uses repeated fluorescent-probe hybridization and imaging to localize RNA targets in tissue at cellular resolution. Visium offerings include HD Whole Transcriptome and HD 3′ Gene Expression assays; Xenium supports fresh-frozen and FFPE tissue and uses validated or custom gene panels. [4](https://app.finbar.com/go?id=P23646988)[10](https://app.finbar.com/go?id=P31244096) Atera, a spatial platform for whole-transcriptome analysis, is specified for measurement of 18,000-plus genes, up to four slides per run and a 625 mm² imageable area per slide; 10x announced that global commercial shipments had begun in September 2026. [11](https://www.10xgenomics.com/platforms/atera)[12](https://www.10xgenomics.com/instruments/atera-instrument)[13](https://www.prnewswire.com/news-releases/10x-genomics-begins-global-shipments-of-atera-putting-unprecedented-spatial-biology-capabilities-in-researchers-hands-302892198.html)

Software includes Cell Ranger for processing single-cell sequencing data, Loupe Browser for visualization of single-cell, spatial and multiomic data, and Xenium Explorer for exploring in situ expression and tissue patterns. [14](https://app.finbar.com/go?id=P103691241) Service offerings include instrument service agreements, typically one-year extended warranties recognized over the coverage period; Xenium installation and in-person training are also described in the company’s product materials. [15](https://app.finbar.com/go?id=P154440931)[16](https://app.finbar.com/go?id=P121218457) In Q2 2026, consumables represented approximately 87.7% of products-and-services revenue, instruments 5.1% and services 7.2%, calculated from reported revenue of $130.752 million, $7.661 million and $10.681 million, respectively, out of $149.094 million. [17](https://app.finbar.com/go?id=T17816623)
[3](https://app.finbar.com/go?id=P90807722)[9](https://app.finbar.com/go?id=P59641181)[4](https://app.finbar.com/go?id=P23646988)[10](https://app.finbar.com/go?id=P31244096)[11](https://www.10xgenomics.com/platforms/atera)[12](https://www.10xgenomics.com/instruments/atera-instrument)[13](https://www.prnewswire.com/news-releases/10x-genomics-begins-global-shipments-of-atera-putting-unprecedented-spatial-biology-capabilities-in-researchers-hands-302892198.html)[14](https://app.finbar.com/go?id=P103691241)[15](https://app.finbar.com/go?id=P154440931)[16](https://app.finbar.com/go?id=P121218457)[17](https://app.finbar.com/go?id=T17816623)[17](https://app.finbar.com/go?id=T17816623)[17](https://app.finbar.com/go?id=T17816623)[17](https://app.finbar.com/go?id=T17816623)[11](https://www.10xgenomics.com/platforms/atera)[12](https://www.10xgenomics.com/instruments/atera-instrument)[13](https://www.prnewswire.com/news-releases/10x-genomics-begins-global-shipments-of-atera-putting-unprecedented-spatial-biology-capabilities-in-researchers-hands-302892198.html)

## Geographic presence

10x Genomics’ global headquarters, R&D facilities, and manufacturing and distribution centers are in Pleasanton, California. The company also reports a manufacturing and distribution center in Singapore and a manufacturing center in Taiwan. Its commercial organization had 473 full-time employees at year-end 2025; the company does not report a geographic breakdown of its total workforce, but says a significant portion of its sales and customer-service personnel are in the United States. [18](https://app.finbar.com/go?id=P54175173)[5](https://app.finbar.com/go?id=P4179124)[6](https://app.finbar.com/go?id=P51893903)

In FY2025, revenue by customer location was $346.512 million in the United States (53.9%), $12.261 million in the Americas excluding the U.S. (1.9%), $161.716 million in Europe, the Middle East and Africa (25.2%), $70.264 million in China (10.9%), and $52.070 million in Asia-Pacific excluding China (8.1%); total revenue was $642.823 million. [19](https://app.finbar.com/go?id=T3306296) The company sells in more than 50 countries, through direct sales in North America and certain regions of Europe, Asia and Oceania, as well as third-party distributors across parts of the Americas, Asia, Europe, Oceania, the Middle East and Africa. Approximately 44% of FY2025 revenue came from customers outside North America. [5](https://app.finbar.com/go?id=P4179124)[20](https://app.finbar.com/go?id=P32512098)
[18](https://app.finbar.com/go?id=P54175173)[5](https://app.finbar.com/go?id=P4179124)[6](https://app.finbar.com/go?id=P51893903)[19](https://app.finbar.com/go?id=T3306296)[19](https://app.finbar.com/go?id=T3306296)[19](https://app.finbar.com/go?id=T3306296)[19](https://app.finbar.com/go?id=T3306296)[19](https://app.finbar.com/go?id=T3306296)[19](https://app.finbar.com/go?id=T3306296)[20](https://app.finbar.com/go?id=P32512098)

## Business segments

10x Genomics reports one operating segment, managed on a consolidated basis; its disclosures do not present Single Cell and Spatial as separate reportable segments. Instead, revenue is disaggregated by source— instruments, consumables, services, and license and royalty revenue—and, for instruments and consumables, by Single Cell and Spatial product lines. Its portfolio includes Chromium, Visium CytAssist, and Xenium Analyzer instruments, related consumables, software, and instrument services. [21](https://app.finbar.com/go?id=P103543152)[22](https://app.finbar.com/go?id=P79037246)

For FY2025, total revenue was $642.8 million. Consumables contributed $507.2 million (78.9% of revenue)—$363.2 million from Single Cell (56.5%) and $144.0 million from Spatial (22.4%). Instruments contributed $56.8 million (8.8%)—$22.7 million Single Cell (3.5%) and $34.1 million Spatial (5.3%). Services contributed $32.7 million (5.1%), and license and royalty revenue contributed $46.1 million (7.2%). These are revenue categories and product-line splits, not separate reportable segments. [23](https://app.finbar.com/go?id=P36236767)

The company also discloses revenue by customer geography: FY2025 Americas $358.8 million (55.8%), EMEA $161.7 million (25.2%), and Asia-Pacific $122.3 million (19.0%). [19](https://app.finbar.com/go?id=T3306296)
[21](https://app.finbar.com/go?id=P103543152)[22](https://app.finbar.com/go?id=P79037246)[23](https://app.finbar.com/go?id=P36236767)[19](https://app.finbar.com/go?id=T3306296)[24](https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm)

## Company history

10x Genomics was incorporated in Delaware on July 2, 2012, initially as Avante Biosystems. Co-founded by Serge Saxonov and Benjamin Hindson, the company adopted the name 10x Genomics in November 2014. [25](https://app.finbar.com/go?id=P17429263)[26](https://app.finbar.com/go?id=P24514239) It launched its first product in 2015, establishing its Chromium platform for single-cell analysis. [7](https://app.finbar.com/go?id=P23115492)[3](https://app.finbar.com/go?id=P90807722)

In 2018, 10x acquired Spatial Transcriptomics, extending its work into spatial gene-expression analysis. [27](https://www.prnewswire.com/news-releases/10x-genomics-acquires-spatial-transcriptomics-300762546.html) The company introduced its Visium spatial gene-expression solution and completed an initial public offering in 2019. [28](https://pages.10xgenomics.com/wbr-visium-launch-series.html)[25](https://app.finbar.com/go?id=P17429263) In 2020, it acquired CartaNA and announced an agreement to acquire ReadCoor to develop in situ analysis capabilities. [29](https://www.sec.gov/Archives/edgar/data/1770787/000177078720000003/txg-20201005xexx991.htm) It launched its Xenium in situ platform in 2022. [10](https://app.finbar.com/go?id=P31244096)

In August 2025, 10x acquired Scale Bio. [30](https://app.finbar.com/go?id=P99127345) In 2026, it introduced Atera, a platform for in situ spatial biology, and announced an agreement to acquire Proteintech Genomics to expand its proteomics capabilities. [31](https://www.prnewswire.com/news-releases/10x-genomics-introduces-atera-a-new-platform-to-redefine-how-biology-is-measured-and-understood-302746542.html)[32](https://www.prnewswire.com/news-releases/10x-genomics-acquires-proteintech-genomics-a-division-within-proteintech-group-302794694.html)
[25](https://app.finbar.com/go?id=P17429263)[26](https://app.finbar.com/go?id=P24514239)[7](https://app.finbar.com/go?id=P23115492)[3](https://app.finbar.com/go?id=P90807722)[10](https://app.finbar.com/go?id=P31244096)[30](https://app.finbar.com/go?id=P99127345)[27](https://www.prnewswire.com/news-releases/10x-genomics-acquires-spatial-transcriptomics-300762546.html)[28](https://pages.10xgenomics.com/wbr-visium-launch-series.html)[29](https://www.sec.gov/Archives/edgar/data/1770787/000177078720000003/txg-20201005xexx991.htm)[31](https://www.prnewswire.com/news-releases/10x-genomics-introduces-atera-a-new-platform-to-redefine-how-biology-is-measured-and-understood-302746542.html)[32](https://www.prnewswire.com/news-releases/10x-genomics-acquires-proteintech-genomics-a-division-within-proteintech-group-302794694.html)

## Sources

1. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P88187382)
2. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P26214981)
3. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P90807722)
4. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P23646988)
5. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P4179124)
6. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P51893903)
7. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P23115492)
8. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P26043104)
9. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P59641181)
10. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P31244096)
11. [www.10xgenomics.com](https://www.10xgenomics.com/platforms/atera)
12. [www.10xgenomics.com](https://www.10xgenomics.com/instruments/atera-instrument)
13. [www.prnewswire.com](https://www.prnewswire.com/news-releases/10x-genomics-begins-global-shipments-of-atera-putting-unprecedented-spatial-biology-capabilities-in-researchers-hands-302892198.html)
14. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P103691241)
15. [10x Genomics, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P154440931)
16. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P121218457)
17. [10x Genomics, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T17816623)
18. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P54175173)
19. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T3306296)
20. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P32512098)
21. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P103543152)
22. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P79037246)
23. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P36236767)
24. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm)
25. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P17429263)
26. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P24514239)
27. [www.prnewswire.com](https://www.prnewswire.com/news-releases/10x-genomics-acquires-spatial-transcriptomics-300762546.html)
28. [pages.10xgenomics.com](https://pages.10xgenomics.com/wbr-visium-launch-series.html)
29. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1770787/000177078720000003/txg-20201005xexx991.htm)
30. [10x Genomics, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P99127345)
31. [www.prnewswire.com](https://www.prnewswire.com/news-releases/10x-genomics-introduces-atera-a-new-platform-to-redefine-how-biology-is-measured-and-understood-302746542.html)
32. [www.prnewswire.com](https://www.prnewswire.com/news-releases/10x-genomics-acquires-proteintech-genomics-a-division-within-proteintech-group-302794694.html)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.